Helix Biopharma Corp Stock Buy Hold or Sell Recommendation
| HBP Stock | CAD 0.87 0.04 4.82% |
Assuming the 90 days trading horizon and your typical level of risk aversion, our recommendation regarding Helix BioPharma Corp is 'Strong Sell'. The recommendation algorithm takes into account all of Helix BioPharma's available fundamental, technical, and predictive indicators you will find on this site.
Check out Helix BioPharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Helix and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Helix BioPharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Helix |
Execute Helix BioPharma Buy or Sell Advice
The Helix recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Helix BioPharma Corp. Macroaxis does not own or have any residual interests in Helix BioPharma Corp or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Helix BioPharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Helix BioPharma Trading Alerts and Improvement Suggestions
| Helix BioPharma Corp generated a negative expected return over the last 90 days | |
| Helix BioPharma Corp has high historical volatility and very poor performance | |
| Helix BioPharma Corp has some characteristics of a very speculative penny stock | |
| Helix BioPharma Corp has high likelihood to experience some financial distress in the next 2 years | |
| Helix BioPharma Corp has accumulated 1.58 M in total debt. Helix BioPharma Corp has a current ratio of 0.36, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Helix BioPharma until it has trouble settling it off, either with new capital or with free cash flow. So, Helix BioPharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Helix BioPharma Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Helix to invest in growth at high rates of return. When we think about Helix BioPharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (9.26 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Helix BioPharma Corp has accumulated about 938 K in cash with (5.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Latest headline from news.google.com: Helix BioPharma Corp. Announces Resignation of Praveen Varshney as Chief Financial Officer - Marketscreener.com |
Helix BioPharma Returns Distribution Density
The distribution of Helix BioPharma's historical returns is an attempt to chart the uncertainty of Helix BioPharma's future price movements. The chart of the probability distribution of Helix BioPharma daily returns describes the distribution of returns around its average expected value. We use Helix BioPharma Corp price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Helix BioPharma returns is essential to provide solid investment advice for Helix BioPharma.
| Mean Return | -0.12 | Value At Risk | -10.62 | Potential Upside | 9.35 | Standard Deviation | 8.12 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Helix BioPharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Helix BioPharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Helix BioPharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Helix BioPharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Helix stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.67 | |
β | Beta against Dow Jones | 4.18 | |
σ | Overall volatility | 8.20 | |
Ir | Information ratio | -0.03 |
Helix BioPharma Volatility Alert
Helix BioPharma Corp is displaying above-average volatility over the selected time horizon. Helix BioPharma Corp is a potential penny stock. Although Helix BioPharma may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Helix BioPharma Corp. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Helix instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Helix BioPharma Fundamentals Vs Peers
Comparing Helix BioPharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Helix BioPharma's direct or indirect competition across all of the common fundamentals between Helix BioPharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Helix BioPharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Helix BioPharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Helix BioPharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Helix BioPharma to competition |
| Fundamentals | Helix BioPharma | Peer Average |
| Return On Equity | -22.21 | -0.31 |
| Return On Asset | -4.59 | -0.14 |
| Current Valuation | 41.57 M | 16.62 B |
| Shares Outstanding | 49.02 M | 571.82 M |
| Shares Owned By Insiders | 2.15 % | 10.09 % |
| Number Of Shares Shorted | 781 | 4.71 M |
| Price To Earning | (7.09) X | 28.72 X |
| Price To Book | 77.46 X | 9.51 X |
| EBITDA | (9.38 M) | 3.9 B |
| Net Income | (9.26 M) | 570.98 M |
| Cash And Equivalents | 938 K | 2.7 B |
| Cash Per Share | 0.01 X | 5.01 X |
| Total Debt | 1.58 M | 5.32 B |
| Current Ratio | 0.37 X | 2.16 X |
| Book Value Per Share | (0) X | 1.93 K |
| Cash Flow From Operations | (5.22 M) | 971.22 M |
| Short Ratio | 0.04 X | 4.00 X |
| Earnings Per Share | (1.05) X | 3.12 X |
| Target Price | 2.5 | |
| Number Of Employees | 7 | 18.84 K |
| Beta | -0.84 | -0.15 |
| Market Capitalization | 42.65 M | 19.03 B |
| Total Asset | 1.49 M | 29.47 B |
| Retained Earnings | (210.67 M) | 9.33 B |
| Working Capital | (123 K) | 1.48 B |
| Net Asset | 1.49 M |
Helix BioPharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Helix . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Helix BioPharma Buy or Sell Advice
When is the right time to buy or sell Helix BioPharma Corp? Buying financial instruments such as Helix Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Helix BioPharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Biotech Thematic Idea Now
Biotech
Companies specialized in biotechnology production and delivery of pharmaceuticals services. The Biotech theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Biotech Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Helix Stock
Helix BioPharma financial ratios help investors to determine whether Helix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.